Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 28Genitourinary 10Breast 7Tumor-Agnostic 5Gastrointestinal 5Thoracic 4Other solid neoplasm 4Dermatologic 2Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Head & Neck 1CNS 1

Conditions

Uveal Melanoma 1Mesothelioma 1Melanoma 1Glioblastoma 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1

Interventions

Ipilimumab 123pembrolizumab 101Nivolumab 100aldesleukin 89Cyclophosphamide 85fludarabine phosphate 64Interleukin-2 58Dacarbazine 573-ingenyl angelate 42Vemurafenib 39Temozolomide 39Imiquimod 39trametinib 37sargramostim 37Peripheral Blood Stem Cell Transplantation 36incomplete Freund's adjuvant 35dabrafenib 32fludarabine 31Radiotherapy 31Aminolevulinic Acid 30Bevacizumab 29Carboplatin 28Whole-Body Irradiation 25Photochemotherapy 25Paclitaxel 25Filgrastim 25Biopsy 25Interferon-alpha 24Cisplatin 23Sorafenib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × niraparib × Dermatologic × Clear all
NCT03207347 2023-09-15

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

University of Florida

Phase 2 Completed
37 enrolled 15 charts
DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma, Carcinoma, Renal Cell, Mesothelioma, Cholangiocarcinoma

NCT01294735 2012-08-15

Study of the Safety and Efficacy of MK-4827 Given With Temozolomide in Participants With Advanced Cancer (MK-4827-014 AM1)

Merck Sharp & Dohme LLC

Phase 1 Completed
19 enrolled
CNSDermatologic

Glioblastoma, Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡